31/08/2017

Congratulations, UHREG!

Paul Ehrlich Institute approves cGVHD Trial

Our German clinical partner Universitätsklinikum Regensburg (UHREG) has officially received ethics and Governmental approval for the manufacturing and application of an advanced therapy medicinal product (ATMP). This means they are now able to run their cGVHD trial as planned, infusing FACS-sorted and in vitro expanded Tregs. The first patient is booked for treatment this week – watch this space!


Photo: UHREG's GMP facility, the José Carreras Centre.

Newsletter Subscription

Click to subscribe to our TREGeneration newsletter!

Click to read the latest issue 

EUROPA - NEWS

What's new in Health and Life Sciences? Click here for news from the European Commission.

Search
Home
Menu
Top

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

Paul Ehrlich Institute approves cGVHD Trial Read more

Social Media

LinkedIn TREGeneration